methyl N-[(1R)-2-[(2S)-2-[17-[2-[(2S)-1-[2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]-21-oxa-6,8-diazapentacyclo[11.8.0.02,10.05,9.014,19]henicosa-1(13),2(10),3,5(9),7,11,14(19),15,17-nonaen-7-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 萘并吡喃类
• 英文名称: methyl N-[(1R)-2-[(2S)-2-[17-[2-[(2S)-1-[2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]-21-oxa-6,8-diazapentacyclo[11.8.0.02,10.05,9.014,19]henicosa-1(13),2(10),3,5(9),7,11,14(19),15,17-nonaen-7-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate
• 化学式: C₄₆H₄₈N₈O₇
• 分子量: 824.9
• InChiKey: BNOFXIQSSHNQCH-WMLGNSFJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  61
• 可旋转键数：
  11
• 环数：
  9.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  184
• 氢给体数：
  4
• 氢受体数：
  9

文献信息

• ANTIVIRAL COMPOUNDS
  申请人：Bacon Elizabeth M.

  公开号：US20140112885A1

  公开（公告）日：2014-04-24

  The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  本公开涉及抗病毒化合物、含有此类化合物的组合物、包括给予此类化合物的治疗方法，以及用于制备此类化合物的工艺和中间体。
• 9-(1H-IMIDAZOL-5-YL)-1,11-DIHYDROISOCHROMENO[4',3':6,7]NAPHTHO[1,2-D]IMIDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF HCV NS5A
  申请人：Gilead Pharmasset LLC

  公开号：EP3239153A1

  公开（公告）日：2017-11-01

  The disclosure is related to anti-viral compounds of formula (I)         E1a-V1a-C(=O)-P1a-W1a-P1b-C(=O)-V1b-E1b     (I) wherein W1a is wherein Y5 is -CH 2-O- or -C(=O)-O-; X5 is -CH=CH-; and W1a is optionally substituted with halo or alkyl; and to compositions containing such compounds for use in the prophylactic or therapeutic treatment of hepatitis C.

  本公开涉及式 (I) 的抗病毒化合物 E1a-V1a-C(=O)-P1a-W1a-P1b-C(=O)-V1b-E1b (I) 其中 W1a 是 其中 Y5 是-CH 2-O- 或-C(=O)-O-； X5是-CH=CH-；和 W1a任选被卤素或烷基取代； 以及含有此类化合物的用于丙型肝炎预防或治疗的组合物。
• CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS
  申请人：Gilead Pharmasset LLC

  公开号：EP3431477A1

  公开（公告）日：2019-01-23

  The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  本公开涉及抗病毒化合物、含有此类化合物的组合物、包括施用此类化合物的治疗方法，以及用于制备此类化合物的工艺和中间体。
• Antiviral compounds
  申请人：GILEAD PHARMASSET LLC

  公开号：US10344019B2

  公开（公告）日：2019-07-09

  The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  本发明涉及抗病毒化合物、含有此类化合物的组合物、包括施用此类化合物的治疗方法，以及制备此类化合物的工艺和中间体。
• US8921341B2
  申请人：——

  公开号：US8921341B2

  公开（公告）日：2014-12-30